An observational study in Cervical Intraepithelial Neoplasia, sponsored by Shufang Chang. Status unknown at 1 site in China. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-18.
Sponsored by Shufang Chang · Observational
Cervical cancer is the fourth leading cause of cancer death in women worldwide, and cervical intraepithelial neoplasia (CIN) can progress to cervical cancer. Therefore, timely treatment of CIN is critical in preventing the occurrence of cervical cancer. With the implementation and promotion of the World Health Organization's 2030 Global Strategy for the Elimination of Cervical Cancer, an increasing number of women are detecting and treating CIN at an earlier stage. Common treatment methods include ablation treatment and excision treatment, but for women who are planning to have children, the risk of cervical insufficiency and pregnancy complications is greatly increased after excisional treatment, so ablation treatment seems to be a better choice.
Focused ultrasound (FUS) is a new ablation method for the treatment of CIN that has received a lot of attention because of its unique ablation mode (from inside to outside) and lack of smoke, ionizing radiation, and other side effects. Preliminary studies have found that FUS treatment is safe and effective at reversing CIN, with curative effects comparable to traditional ablation and excisional treatments. However, few studies have reported the mechanism of FUS in the treatment of CIN. As a kind of ablation treatment, it is unclear whether FUS, like other ablation treatment mechanisms, stimulates the immune response of the body to promote the reversal of the lesions by in situ necrotic lesions.
There is limited evidence to support the link between FUS, immune response, and CIN. Fu compared the cervical tissues of patients with CIN before and after FUS treatment and found that the expression of p16 and ki-67 decreased while the expression of Fas increased after treatment, indicating that FUS can regulate cell proliferation and apoptosis-related proteins, and promote the recovery of cervical tissues. More recently, Zeng compared the cervical immune microenvironment in patients with CIN before and after FUS treatment. It has shown that FUS treatment increased the expression of ERAP1 in cervical tissue and decreased the level of IgA and IL-10 in cervicovaginal lavage, which indicated that FUS treatment can regulate the cervical immune microenvironment.
The immune response of the body is a dynamic and changing process. Any attempt to infer further on immunological changes before and after treatment require dynamic studies that will explore how FUS ablation of the disease, i.e. CIN, will alter the cervical immune microenvironment. The local immunological indexes produced by FUS treatment of CIN should be a dynamic process, and more time points should be selected to monitor the changes in these immunological indexes. Currently, there are no such studies.
At the same time, a large number of studies suggest that Vaginal Microbiota(VMB) can alter the cervicovaginal immune microenvironment and Lactobacillus spp. depleted and high diversity of VMB is prone to form a pro-inflammatory environment, which in turn promotes the progression of CIN and the occurrence of cervical cancer. Therefore, to further explore the mechanisms of FUS ablation treatment of CIN and clearance of HPV, this interventional study was conducted to dynamically observe the changes in the VMB and mucosal immunity in patients with CIN before and after FUS ablation treatment and to compare with untreated healthy controls. This may also have implications for the persistence and recurrence of lesions.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 90 is below the median of 204 across 1,683 observational studies indexed under Neoplasms.
Browse Neoplasms studies →This is the only study on the registry with Shufang Chang as lead sponsor.
Counted across the registry records on this site, refreshed daily.
We plan to include women with HPV positive, who plan for focused ultrasound ablation treatment for CIN attending the colposcopy clinics at the Second Affiliated Hospital of Chongqing Medical University.
Exclusion Criteria:
HPV positive，pathology result indicate cervical intraepithelial neoplasia
Procedure: Focused Ultrasound
HPV negative, normal cytology
Focused ultrasound generates heat effects, mechanical effects and cavitation effects that denature the diseased tissues, facilitate necrosis and allow them to be replaced by surrounding normal healthy tissues.
Also known as: High-Intensity Focused Ultrasound Ablation
Immunological indexes
Immunological indexes(IFN-γ、IL-8、IL-10、IL-1β、SIgA) in cervical secretions will be measured by enzyme-linked immunosorbent assay (ELISA).
Time frame: We will get specimens in therapeutic day, after treatment 7-10 days，84-112days and 168-196 days respectively.
Anti-microbial peptides
Anti-microbial peptides levels (hBD-1、SLPI ) in cervical secretions will be measured by enzyme-linked immunosorbent assay (ELISA).
Time frame: We will get specimens in therapeutic day, after treatment 7-10 days，84-112 days and 168-196 days respectively.
Vaginal microbiota
We will evaluate vaginal microbiota by bacterial diversity and richness, and Lactobacillus grading.
Time frame: We will get specimens before therapeutic day, after treatment 84-112 days and 168-196 days respectively.
HPV genotyping
HPV DNA testing and genotyping
Time frame: We will get specimens before therapeutic day, after 84-112 days and 168-196 days respectively.
Cytology
Thinprep cytologic test
Time frame: We will get specimens before therapeutic day, after treatment 84-112 days and 168-196 days respectively.
Measurement of dimensions of cervix
Transvaginal ultrasonography is performed to measure the dimensions of cervix.
Time frame: We will measure the dimensions of cervix before therapeutic day and after treatment 84-112 days respectively.
Antisperm antibody
Antisperm antibody in cervical secretions will be measured by enzyme-linked immunosorbent assay (ELISA).
Time frame: We will get specimens before therapeutic day, after treatment 84-112 days and 168-196 days respectively.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.